SEP 26, 2022 3:00 AM PDT

Clinical Trial Suggests Oncolytic Virus Effective in Combination with Immune Checkpoint Inhibition

WRITTEN BY: Katie Kokolus

One type of cancer immunotherapy, called oncolytic viral therapy, works by infecting cancer cells with a specific virus.  Some oncolytic viruses occur naturally, while others result from specialized engineering performed in a laboratory.  Oncolytic viruses replicate within cancer cells, proving a mechanism to kill cancer cells without damaging healthy cells.  The use of oncolytic viral therapy for cancer treatment is rapidly growing.  Currently, clinicaltrials.gov lists over 100 ongoing or recently completed Clinical Trials testing the efficacy of various oncolytic viruses. 

A research team recently presented promising data emerging from one multicenter Clinical Trial at the European Society for Medical Oncology Annual Meeting.  The trial tests a drug called RP2, an oncolytic virus developed from the herpes simplex virus type 1 (HSV-1).  In part, the RP2 oncolytic virus is engineered to inhibit CLTA-4 signaling in an effort to improve the ability of T cells to kill cancer cells.  The researchers tested RP2 both as a monotherapy and in combination with nivolumab, an immune checkpoint inhibitor targeting PD-1.  Patients enrolled in the trial received eight doses of RP2 plus nivolumab administered every other week for four months and then monthly for 20 months.  

Nine patients received RP2 monotherapy, of which three exhibited responses lasting at least 15 months.  Twenty patients received RP2 in combination with nivolumab.  RP1 plus nivolumab demonstrated significant responses in various cancer types, including cutaneous melanoma (44.4%), uveal melanoma (25%), and head and neck carcinoma (33%).  Overall, seven out of 20 patients who responded to the therapy had previously failed treatment with PD-1 inhibition.  Additionally, six of the seven responders had maintained durable responses for over 425 days at the time of the presentation. 

Many studies indicate that immune cell infiltration to the tumor correlates to response to immune checkpoint inhibitors.  In order to evaluate the immune cell profile of the responding tumors, researchers performed immunohistochemistry (IHC).  The IHC analysis revealed that the treatment increased infiltration of CD8 T cells, also known as cytotoxic T lymphocytes (CTLs), the subset of immune cells responsible for killing cancer cells.  Further, the researchers evaluated the ratio of CD8 T cells to immunosuppressive cells positive for Foxp3, known as regulatory T cells.  The analysis showed that treatment correlated to a favorable balance of CD8/Foxp3 cells. 

The researchers conclude that RP2, combined with nivolumab, generated durable systemic responses in patients with advanced cancers who have failed prior treatment options.  Although early, this data suggests a new potential treatment option for patients without other therapeutic options. 

 

Sources: Front Oncol, ESMO Congress, NLM, EClinicalMedicine

About the Author
PhD
PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
AUG 03, 2022
Cancer
Guide to Adherent Cell Culture Basics: Seeding, Expanding, and Harvesting
AUG 03, 2022
Guide to Adherent Cell Culture Basics: Seeding, Expanding, and Harvesting
Cell culturing is hard work. Because it's a highly technical process, there's a lot that can go wrong  ...
JUL 21, 2022
Cell & Molecular Biology
'Junk' DNA May Stall Replication, Increasing Cancer Risk
JUL 21, 2022
'Junk' DNA May Stall Replication, Increasing Cancer Risk
Huge sections of the human genome are made up of highly repetitive sequences, areas where bases like ATATAT repeat in lo ...
JUL 28, 2022
Cancer
Potential Marker for Prostate Cancer Prognosis Identified
JUL 28, 2022
Potential Marker for Prostate Cancer Prognosis Identified
Cytokines, proteins that affect the immune system, can elicit their effects in either a beneficial or an inhibitory capa ...
SEP 05, 2022
Cancer
Grover Cleveland's Covert Cancer Excision
SEP 05, 2022
Grover Cleveland's Covert Cancer Excision
Labor Day, the American holiday created to celebrate the “social and economic achievements” of the workforce ...
OCT 31, 2022
Cancer
Pumpkins: A Trick or a Treat for Cancer?
OCT 31, 2022
Pumpkins: A Trick or a Treat for Cancer?
Cancer is a disease that impacts the whole person, wreaking havoc on an individual’s emotional and physical well-b ...
NOV 09, 2022
Genetics & Genomics
Want to Study Copy Number Alterations in Cells? Bring MACHETE
NOV 09, 2022
Want to Study Copy Number Alterations in Cells? Bring MACHETE
Sure, MACHETE is a cool name, but the researchers that developed the technique are hoping people don't focus solely on t ...
Loading Comments...